China Pharma and Biotech Press Review (CPBPR) is a weekly newsletter that brings together the latest news about Health policies and the Pharmaceutical, Biotech, Diagnostics, and Medtech industries in China.
CPBPR delivers selected articles plus industry insights from our Consultants directly to your inbox, keeping you posted on R&D, licensing deals, M&A, regulatory reforms, e-Health, as well as must-know strategies, market trends, and drug approvals.
Get Right to What You Need
Do you like to jump straight to the newsletter articles that interest you most? Good news. The email version of CPBPR provides a short summary of each article scooped in the current issue. From there, you can pick the articles you want to read, click "Read the full story," and read articles online.
The newsletter issue you receive in your inbox mirrors the issue available online. After you have read an article, you can either return to your email version or navigate through the website to other articles from that issue and the former. You will also be able to read articles directly from their sources.
Benefit from our Insights
From hundreds of articles and publications available online each week, we bring you a selected dozen. Let us share with you why these reflect China’s Life Sciences market dynamics, and how they are relevant to our industry in the Asia-Pacific region.